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OBJECTIVES We sought to evaluate the effects of hydroxymethylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors on vascular smooth muscle cell (VSMC) proliferation in vitro and
neointimal formation in vivo after vascular injury.
BACKGROUND Neointimal hyperplasia after vascular injury is responsible for restenosis after arterial stenting,
whereas arterial remodeling and neointimal formation are the causes of restenosis after
percutaneous transluminal coronary angioplasty.
METHODS We assessed the effect of simvastatin on in vitro VSMC proliferation. To study the effects of
simvastatin in vivo, balloon injury and stent deployment were performed in the common
carotid artery of rats. Neointimal area was measured two weeks later in the balloon injury
model and three weeks after stent deployment.
RESULTS Simvastatin markedly inhibits VSMC proliferation in vitro. In vivo, simvastatin reduced, in
a dose-dependent manner, the neointimal area and the neointima-media ratio after balloon
injury from 0.266 6 0.015 mm2 to 0.080 6 0.026 mm2 and from 1.271 6 0.074 to 0.436 6
0.158 (p , 0.001 vs. control rats) at the highest dose. Simvastatin also significantly reduced
the neointimal formation and the neointima-media ratio after stenting from 0.508 6 0.035
mm2 to 0.362 6 0.047 mm2 (p , 0.05 vs. control rats) and from 2.000 6 0.136 to 1.374 6
0.180 (p , 0.05 vs. control rats). The vessel thrombosis rate after stent deployment was 30%
in the control group and 11.1% in the treated group (p 5 NS). Moreover, the systemic
administration of simvastatin did not affect hepatic and renal functions, blood pressure or
heart rate.
CONCLUSIONS Simvastatin potently inhibits VSMC proliferation in vitro and reduces neointimal formation
in a rat model of vascular injury. (J Am Coll Cardiol 2000;35:214–21) © 1999 by the
American College of Cardiology
Several clinical studies have demonstrated the beneficial
effects of hydroxymethylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors in primary (1,2) and secondary preven-
tion in reducing cardiovascular mortality (3–5). The anti-
atherosclerotic effect of these drugs has been linked to their
hypolipidemic properties (6–9). However, clinical studies
have demonstrated that the potency of these drugs in
reducing cardiovascular events is independent of the basal
cholesterol levels (5,10,11). In fact, the HMG-CoA reduc-
tase inhibitors, such as simvastatin, not only reduce the
plasma cholesterol levels but also competitively inhibit
intracellular synthesis of mevalonate, a precursor of non-
sterol compounds, such as geranylgeranyl and farnesyl,
involved in cell functions and proliferation (12–18).
The effect of simvastatin on the synthesis of farnesyl
radicals is responsible for the intracellular inhibition of the
ras-raf-MAPKK (mitogen-activated protein kinase kinase)
protein’s signal transduction pathway activation (12). Ras
proteins and their relatives play a critical role in the control
of normal and transformed cell growth. Ras proteins are
members of a family of glutamyl transpeptidases (GTPases),
which includes proteins involved in protein synthesis and
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signal tansduction (heterotrimeric G protein). The anchor-
age of GTPases to various cellular membranes is also critical
for their proper function and is regulated by prenyl trans-
ferases. These enzymes catalyze the reaction that leads to
linkage of farnesyl and geranylgeranyl groups to ras proteins
(19). We previously demonstrated that the ras pathway plays
a key role in the neointimal formation after balloon injury
(19,20).
Conflicting clinical data are available on the efficacy of
HMG-CoA reductase inhibitors on restenosis after balloon
angioplasty (21–26). However, recent studies have demon-
strated that the major mechanism responsible for restenosis
after angioplasty is arterial remodeling, a phenomenon that
is not influenced by HMG-CoA reductase inhibitors
(27,28). This may explain the conflicting current data on the
effects of HMG-CoA reductase inhibitors on restenosis
after percutaneous transluminal coronary angioplasty
(PTCA). Although stent deployment has been shown to
reduce the rate of restenosis as compared with balloon
angioplasty (29,30), in-stent restenosis is a significant and
growing clinical problem. It is now well established that the
proliferation of smooth muscle cells is the only mechanism
responsible for restenosis after arterial stenting (28,31,32)
and contributes to restenosis after balloon angioplasty
(33,34).
Accordingly, the aims of the present study were to assess
the effect of simvastatin on in vivo neointimal formation
induced by vascular injury. The role of the HMG-CoA
reductase inhibitor simvastatin on vascular smooth muscle
cell (VSMC) proliferation in vitro was also assessed.
METHODS
Cell culture. Smooth muscle cells (A10, thoracic aorta of
the rat) were used to study the effect of simvastatin on cell
proliferation in vitro. Cells were grown in monolayers at
37°C in a humidified atmosphere at 95% carbon dioxide in
10% fetal calf serum (FCS)–Dulbecco Modified Eagles
Medium (DMEM) with 4 mmol/liter L-glutamine, 4.5
g/liter glucose and 1.0 mmol/liter sodium pyruvate. For
growth inhibition experiments, 2 3 104 cells were plated
into a 35-mm plate and grown in 10% FCS-DMEM in the
presence of simvastatin in lactone form (2 mmol/liter) that
was brought into solution by 0.1 mol/liter NaOH to give
the active form, and the pH was adjusted to 7.4 by adding
0.1 mol/liter hydrochloride (Merk-Sharp & Dhome Re-
search, Woodbridge, New Jersey), 25-OH-cholesterol (10
mg/ml) or mevalonic acid (MVA) (100 mmol/liter) (Sigma
Chimica, Milan, Italy), or in the absence of simvastatin
(control). Cell numbers in both conditions were assessed
every 48 h for six days.
Vascular injury induced by balloon dilation or stent
deployment. The rats in this study were handled according
to the animal welfare regulations of the University Federico
II of Naples, and the protocol was approved by the Animal
Use Committee of this institution. All animals received
human care in accordance with the Animal Use Principles
of the American Society of Physiology. All rats were
maintained under identical conditions of temperature (21 6
1°C), humidity (60 6 5%) and light-dark cycle and had free
access to normal rat chow.
Balloon injury. Forty-five Wistar male rats weighing 350
to 400 g (at 14 weeks of age), purchased from Charles River
(Calco, Italy), were included in the present study. The rats
were anesthetized with an intramuscular injection of
100 mg/kg ketamine (Sigma Chimica, Milan, Italy) and
5 mg/kg xylazine (Sigma Chimica). Angioplasty of the
carotid artery was performed using a balloon embolectomy
catheter, as previously described and validated in our labo-
ratory (18,35–37). In brief, the balloon catheter (2F
Fogarty, Edwards Laboratories, Santa Ana, California) was
introduced through the right external carotid artery into the
aorta, and the balloon was inflated at 1.5 atm using a
calibrated, commercially available inflation device (Indefla-
tor Plus 20, Advanced Cardiovascular System, Inc., Te-
mecula, California). The vessel was damaged by passing an
inflated balloon through the lumen three times. Previous
studies performed in our laboratory demonstrated that the
time necessary to pass the inflated balloon catheter back and
forth into the carotid artery three times is 18 s (36).
Therefore, to keep constant the time of the injury (that
might influence the VSMC proliferation) we maintained
constant the time of balloon inflation to 18 s.
Stent deployment. Scimed NIR stents (Boston Scientific
Corporation, Galway, Ireland) (7-cell, 4-mm length),
etched in 316LVM stainless steel and made of a continuous
uniform multicellular design, were implanted. The stents
were manually crimped on a 1.5-mm PTCA balloon cath-
eter (ACS RX Comet, Advanced Cardiovascular System,
Inc.) inflated at 11 atm for 60 s to expand the stent and to
optimize the struts’ apposition against the arterial wall. At
the time of stent implantation, 100 U/kg of heparin was
injected intraperitoneally. No other anticoagulant or anti-
platelet therapy was given either before or after stent
deployment.
The balloon catheter loaded with the stent was intro-
duced using a dissecting microscope (Leica, GZ4) through
Abbreviations and Acronyms
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GTPase 5 glutamyl transpeptidase
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the right external carotid artery into the common carotid
artery and then inflated. The effect of stent implantation on
neointimal formation was assessed 21 days later.
Drug dosage and administration. The HMG-CoA re-
ductase inhibitor simvastatin was randomly administered in
three different protocols: Protocol 1—the drug was admin-
istered orally at the daily dose of 40 mg/kg (n 5 8),
16 mg/kg (n 5 7), 4 mg/kg (n 5 7), 0.04 mg/kg (n 5 9) 14
days before and after balloon injury. Eight animals were
used as the control group: Protocol 2—simvastatin was
administered at 40 mg/kg as in protocol 1, although at the
time of balloon injury MVA (10 mmol/liter) was locally
administered to the injured artery using pluronic gel (n 5
5), with a technique previously described (21,37). Protocol
3—40 mg/kg simvastatin (n 5 10) was administered daily
14 days before and 21 days after stent deployment in the
rats, although in a control group of nine animals the stent
was deployed without drug administration.
Toxicity. To study simvastatin toxicity, laboratory studies
were performed at baseline and two weeks after daily drug
administration (40 mg/kg) (n 5 8).
Morphology. At the time of the final experiment (two
weeks later), the animals were anesthetized with an intra-
muscular injection of 100 mg/kg ketamine and 5 mg/kg
xylazine, and the carotid arteries were fixed by perfusion at
120 mm Hg with 100 ml of phosphate-buffered saline
(PBS, pH 7.2), followed by 80 ml of PBS containing 4%
paraformaldehyde through a large cannula placed in the left
ventricle. The carotid arteries were removed and six cross
sections were cut (each 6 mm thick) from the approximate
mid-portion of the artery, with three of the sections stained
with hematoxylin-eosin to demarcate cell types. The re-
maining three sections were stained with aldehyde fuchsin
and counterstained with Van Gieson’s solution to demarcate
the internal elastic lamina. The sections were photographed
under low power, blindly videodigitized and stored in the
image analysis system (Mipron, Kontron Electronics, Ech-
ing, Germany) in a 512 3 512 matrix with an eight-bit gray
scale and a 12-field view. The media, neointima and vessel
wall were traced carefully, and the ratios between the
neointima and media were calculated (36,37). The intraob-
server variability was already documented (21,36).
In an additional group (n 5 7) the effects of the
anesthesia and the surgical procedure (without the balloon
injury) on VSMC proliferation were also assessed.
Pathologic evaluation. Immediately after the rats’ death,
the arteries were dehydrated and cleared, and then infil-
trated and embedded in a combination of polymethyl-
methacrylate, n-butyl phthalate and benzoil peroxide, as
previously described (38). A tungsten-carbide knife was
used to obtain 6-mm sections from the middle of the stented
arteries. Modified hematoxylin-eosin and elastin stains were
used to stain the plastic-embedded stented segments. The
neointimal area and the neointima-media ratio were calcu-
lated in a blinded manner as described earlier.
Doppler evaluation. To assess vessel patency, right and
left Doppler probes were applied at the time of the final
experiment.
Statistical analysis. All data are presented as the mean
value 6 SEM. Statistical analysis between the groups was
performed by analysis of variance and the unpaired t test
using a Systat program (39). Tukey’s test was applied to
compare single mean values (40). A p value ,0.05 was
considered significant.
RESULTS
Effect of simvastatin on VSMC proliferation in vitro. To
evaluate the effect of simvastatin on VSMC proliferation,
we treated cultures of VSMCs with 2 mmol/liter simvastatin
and analyzed cell growth at different times. Figure 1 shows
that simvastatin markedly inhibited the proliferation of
VSMCs. To demonstrate that the effect of simvastatin on
VSMC proliferation was due to the inhibition of HMG-
CoA reductase, we investigated the effects of this statin on
VSMC proliferation in the presence of 100 mmol/liter
MVA and 25-OH-cholesterol (2 mg/ml). The ability of
MVA to restore VSMC proliferation indicates that the
effect elicited by simvastatin was related to inhibition of the
MVA pathway, whereas the lack of this effect in the
presence of 25-OH-cholesterol may suggest that the anti-
proliferative effect of simvastatin is independent of choles-
terol in the serum (Fig. 1).
Effect of simvastatin on neointimal formation after bal-
loon dilation in vivo. In the sham-operated rats not
subjected to vascular injury, no neointimal formation was
detected and the endothelium was found intact 14 days after
the operation in both carotid arteries of all rats. A repro-
Figure 1. Effects of simvastatin (2 mmol/liter) on the growth
inhibition of rat VSMCs. In treated rats simvastatin (open boxes)
induced a significant inhibition of VSMC proliferation as com-
pared with control rats (solid diamonds). This effect was com-
pletely reversed by addition of mevalonate (100 mmol/liter) to the
medium (open circles), but it was not affected by addition of
25-OH-cholesterol (100 mg/ml) (solid triangles). *p , 0.01 vs.
control rats and simvastatin plus mevalonate treatment.
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ducible neointimal formation was found 14 days after
balloon injury in the control group (neointima 0.266 6
0.015, neointima-media ratio 1.271 6 0.074). In animals
treated with systemic administration of simvastatin, we
observed a significant reduction of both the neointima and
neointima-media ratio in a dose-dependent manner
(Table 1).
Figure 2 shows representative histologic carotid cross
sections two weeks after balloon dilation of rats treated with
different doses of simvastatin.
Interestingly, the local delivery of mevalonate in vivo
prevented the beneficial effects of simvastatin on neointimal
formation. In fact, the neointima-media ratio was 1.271 6
0.074 in control rats, 0.436 6 0.158 after simvastatin and
1.258 6 0.084 after systemic simvastatin administration and
local delivery of mevalonate (Figs. 3,4).
Table 1. Arterial Morphologic Characteristics of Different Groups of Balloon-Injured Animals Included in the Study
Neointima
(mm2)
%
Change
vs.
Control
Group
p
Value
vs.
Control
Group Media (mm2)
p
Value
vs.
Control
Group N/M Ratio
%
Change
vs.
Control
Group
p
Value
vs.
Control
Group
Control rats
(n 5 8)
0.266 6 0.015 — — 0.208 6 0.035 — 1.271 6 0.074 — —
Simvastatin
0.04 mg/kg
(n 5 9)
0.219 6 0.020 224% NS 0.210 6 0.020 NS 1.045 6 0.033 218% NS
Simvastatin
4 mg/kg
(n 5 7)
0.212 6 0.006 226% NS 0.208 6 0.018 NS 1.023 6 0.040 220% NS
Simvastatin
16 mg/kg
(n 5 7)
0.176 6 0.009 232% , 0.05 0.205 6 0.028 NS 0.866 6 0.050 232% , 0.05
Simvastatin
40 mg/kg
(n 5 8)
0.080 6 0.026 269% , 0.001 0.170 6 0.064 NS 0.436 6 0.158 266% , 0.001
Simvastatin
40 mg/kg 1
mevalonate
0.256 6 0.011 21% NS 0.207 6 0.040 NS 1.258 6 0.084 22% NS
10 mmol/liter
(n 5 5)
Data are expressed as the mean value 6 SEM.
N/M 5 neointima-media.
Figure 2. Representative histologic sections stained with
hematoxylin-eosin of the common carotid arteries from (a) a
control rat subjected to only balloon injury; (b) a rat treated with
0.04 mg/kg simvastatin; (c) a rat treated with 4 mg/kg simvastatin;
(d) a rat treated with 16 mg/kg simvastatin; (e) a rat treated with
40 mg/kg simvastatin; and (f) a rat treated with 40 mg/kg
simvastatin plus local administration of mevalonate (10 mmol/
liter).
Figure 3. Neointima-media (N/M) ratio and neointimal cross-
sectional area (neointima) of common carotid arteries from rats
subjected to only balloon injury (solid bars), rats treated with
40 mg/kg per day of simvastatin (open bars) and rats treated with
simvastatin at the highest dose and local administration of meva-
lonate (striped bars). *p , 0.01 vs. control group and mevalonate
group.
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Effect of systemic simvastatin administration on neoin-
timal formation after arterial stenting. As shown in Table
2 in control rats 21 days after arterial stenting, a significant
neointimal formation and neointima-media ratio were ob-
served (0.508 6 0.035 mm2 and 2.008 6 0.136). The
systemic administration of simvastatin reduced the neointi-
mal formation and the neointima-media ratio (0.362 6
0.047 mm2 [p , 0.05 vs. control rats], 1.374 6 0.180 [p ,
0.05 vs. control rats]) (Figs. 5, 6). The rate of stent
thrombosis was 30% in the control group and 11% in the
simvastatin group (p 5 NS).
Effect of systemic simvastatin administration. No differ-
ences in arterial pressure and heart rate were found between
the sham-operated rats and the experimental rats (data not
shown). No hematopoietic, hepatic and renal function
alterations were associated with simvastatin administration
(Table 3). Histologic studies of kidney and liver sections
confirmed these data (data not shown).
DISCUSSION
The major findings of the present study are that simvastatin
reduces the VSMC proliferation in vitro and neointimal
formation induced by vascular injury in vivo.
Mechanisms of restenosis. Treatment of symptomatic
atherosclerotic heart disease has become increasingly fo-
cused on percutaneous catheter-based techniques. However,
restenosis limits the benefit of PTCA occurring in 30% to
60% of patients (41–44). Recently the use of the stent has
been introduced to treat vascular dissections and to achieve
a larger lumen diameter to reduce restenosis (29,30,45).
Unfortunately, the stent also markedly induced proliferation
of VSMCs. In fact, neointimal formation is the only
mechanism responsible for the restenosis after stent deploy-
ment (28) that occurs in ;20% of BENESTENT-like
lesions (29,30) and in ;50% of long lesions and vein grafts
(45–49). Previous studies using intravascular ultrasound
demonstrated that stent deployment abolishes arterial re-
modeling but triggers and may actually increase the neoin-
Figure 4. Percent changes of plasma cholesterol levels (solid
circles) and neointima-media ratio (solid squares) after balloon
injury in rats treated with different simvastatin doses. It is evident
that simvastatin reduced the cholesterol levels by ;20%, indepen-
dent of the simvastatin dose used. In contrast, at the same level of
cholesterol reduction, the effect on the neointima-media ratio after
balloon dilation was more pronounced after increasing the simva-
statin doses. This finding, together with the in vitro data, strongly
suggests that the beneficial effect of simvastatin on the vascular
response to injury is not dependent only on cholesterol level
reduction. *p , 0.05 vs. control group. #p , 0.001 vs. control
group and treatment with 0.04, 4 and 16 mg/kg simvastatin.
Table 2. Arterial Morphologic Characteristics After Stent Deployment
Neointima
(mm2)
%
Change
vs.
Control
Group
p
Value
vs.
Control
Group Media (mm2)
p
Value
vs.
Control
Group N/M Ratio
%
Change
vs.
Control
Group
p
Value
vs.
Control
Group
Control rats 0.508 6 0.035 — — 0.250 6 0.007 — 2.008 6 0.136 — —
(n 5 6)
Simvastatin
40 mg/kg
(n 5 9)
0.362 6 0.04 228% 0.05 0.264 6 0.007 NS 1.374 6 0.180 232% 0.0
Data are expressed as the mean value 6 SEM.
N/M 5 neointima-media.
Figure 5. Neointima-media (N/M) ratio and neointimal cross-
sectional area (neointima) of common carotid arteries from rats
subjected to only NIR 7-cell stent implantation (solid bars); rats
treated with 40 mg/kg per day simvastatin 14 days before and 21
days after stent implantation (open bars). *p , 0.05 vs. control
group.
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timal proliferation responsible for neointimal formation
(31–33). Therefore, increasing evidence suggests a central
role of VSMC proliferation in restenosis after stent deploy-
ment (29) and a relative importance of VSMCs in restenosis
after balloon angioplasty, especially in patients with diabetes
(50–52), unstable angina or hypertension (53,54). A previ-
ous study from our laboratory demonstrated that the local
delivery of a transdominant negative H-ras gene markedly
prevented neointimal formation after balloon injury in rats
(21). This finding was recently confirmed using adenovirus-
mediated gene transfer (55). The inhibition of a protein
downstream from ras, the MAPKK, also prevents neointi-
mal formation after balloon injury (37). Other investigators
have also shown that gene therapy approaches could be used
in experimental animal models to reduce neointimal forma-
tion after balloon injury (56–58). Several studies using
adenovirus gene transfer have shown efficacy in preventing
neointimal proliferation after balloon injury (59–62). These
data, demonstrating the ability of adenoviral vectors to
deliver genes efficiently in VSMCs, could predict their use
in the clinical setting. However, careful and objective trials
in humans are needed to validate this hypothesis.
Inhibition of neointimal hyperplasia by statins. At the
present time, inhibition of the ras pathway is pharmacolog-
ically feasible in the clinical setting using inhibitors of
farnesyl radicals synthesis, such as simvastatin or other
HMG-CoA reductase inhibitors (17,23–25,63). To dem-
onstrate that the effect of simvastatin was independent of
the cholesterol concentration and dependent on the inhibi-
tion of the mevalonate pathway, we performed additional in
vitro and in vivo experiments. The cholesterol that was
added in the in vitro VSMCs did not affect the inhibition of
cell proliferation by simvastatin. In contrast, MVA com-
pletely abolished the effects of simvastatin on cell growth
(Fig. 1). These data were also confirmed in vivo. Our
method, the local administration of mevalonate in pluronic
gel (21,36), allows the study of regional drug administration
without systemic toxic effects and demonstrates, for the first
time in vivo, that the effects of simvastatin on cell prolifer-
ation was dependent of the inhibition of mevalonate (Fig.
3). In the present study, we also assessed the dose response
of simvastatin (Table 1, Fig. 2). The dose that potently
reduced neointimal formation is high as compared with the
dose used in the clinical setting. However, previous studies
demonstrated a species differences in simvastatin metabo-
lism; in fact, the DL50 of this drug in rats is 5 g/kg per day
(Merk-Sharp & Dhome data base), and other animal
studies also used the dose of 10 to 150 mg/kg per day
(10,64).
In this study we used a highly standardized model of
balloon injury introduced by Clowes et al. (65). It has been
demonstrated that in this model the amount of neointimal
hyperplasia is maximal, reaching the plateau at 14 days after
the procedure (66). Therefore, we decided to evaluate the
neointimal area 14 days after balloon injury (36). In con-
trast, we evaluated the effect of stent deployment 21 days
after the procedure. We found, in this model, that the
neointimal formation reaches the maximum at that time
(unpublished data). We started simvastatin administration
14 days before the procedure to achieve a biologic effect.
Shorter pretreatment did not influence neointimal prolifer-
ation after balloon injury and stent deployment.
The difference in the amount of neointima in balloon-
injured arteries and stented arteries may be due to differ-
ences in the nature and extent of vessel injury in the two
models. In fact, stent deployment with a semicompliant
PTCA balloon inflated at high pressures induces a greater
circumferential stretch to the vessel wall, which causes
greater barotrauma as compared with balloon injury alone.
In a previous study, a Silastic collar was applied on the
external surface of the artery, and the effect of simvastatin
and other HMG-CoA reductase inhibitors was assessed
(10). Although the animal model used might be different in
terms of the vascular effects induced by balloon catheter
dilation and stent deployment, a reduction in the neointimal
area in the simvastatin-treated group was documented (10).
Our data also demonstrate that the systemic administration
of simvastatin, at the highest dose used, is able to reduce
neointimal formation by 66% after balloon injury. More
interestingly, the dose of simvastatin used in the present
study did not affect heart rate, blood pressure or liver and
renal function (Table 3) or histology (data not shown). This
Figure 6. Representative histologic sections stained with
hematoxylin-eosin of arteries from (a) a control rat’s carotid artery
after stent deployment; (b) same artery after stent implantation in
a rat treated with 40 mg/kg per day simvastatin.
Table 3. Effect of Simvastatin on Hematologic Variables in Rats
After Balloon Angioplasty
Control
Group
SIM Group
(40 mg/kg)
p
Value
BUN (mg/dl) 43.1 6 3.5 35.16 6 8.4 NS
Creatinine (mg/dl) 0.56 6 0.08 0.41 6 0.05 NS
GOT (IU/liter) 122.5 6 12.6 129 6 11.5 NS
GPT (IU/liter) 39.16 6 8.6 43.1 6 6.7 NS
Cholesterol (mg/dl) 59.33 6 8.23 49.5 6 6.23 , 0.05
CK (IU/liter) 919 6 24 926 6 32 NS
Data are expressed as the mean value 6 SEM.
BUN 5 blood urea nitrogen; CK 5 creatine kinase; GOT 5 glutamic oxaloacetic
transaminase; GPT 5 glutamic pyruvic transaminase; SIM 5 simvastatin.
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is an important finding; in fact, our study demonstrates that
commercially available drugs such as simvastatin, systemi-
cally administered, can prevent a very localized phenome-
non such as neointimal hyperplasia after vascular injury.
Systemic administration of a therapeutically active agent
may represent a distinct advantage over local delivery
systems. In fact, previous studies from our and other
laboratories demonstrated the efficacy of using pluronic gel
applied on the external surface of the artery or adenovirus-
mediated gene therapy to prevent the in vivo proliferation of
VSMCs. However, these techniques are not clinically fea-
sible (18,21,35,37,55,59–62). In addition, intravascular
brachytherapy is an emerging therapeutic strategy to prevent
restenosis after angioplasty and stenting. It is obvious that
the unwanted biologic effects of radiation and the effort to
organize the use of radiation in the catheterization labora-
tory may limit the extensive use of this new therapeutic
option.
Study limitations. Extreme caution should be used in
extrapolating the experimental data presented in this study,
using VSMC culture or the rat angioplasty model, to the
clinical setting. The role of other statins should also be
studied. Therefore, further studies should be performed to
evaluate the effects of HMG-CoA reductase inhibitors on
stent restenosis in a model of larger animals and eventually
in humans.
Conclusions. Simvastatin potently affects in vitro VSMC
proliferation. More interestingly, the HMG-CoA reductase
inhibitors prevented neointimal formation after vascular
injury. This beneficial effect was abolished using local
administration of mevalonate.
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